Hepatitis E
Symptoms, Doctors, Treatments, Advances & More

Hepatitis E Overview

Save information for later
Sign Up

Learn About Hepatitis E

View Main Condition: Hepatitis

What is the definition of Hepatitis E?
Hepatitis E is a viral infection of liver that causes inflammation and can damage organs. The disease usually causes acute, short-term infection but can become chronic in people with weakened immune systems, in which case the disease can cause cirrhosis, liver failure, or even death. Hepatitis E is spread by the fecal-oral route, mainly by drinking contaminated water. Other causes are eating undercooked meat from infected animals, such as pork or deer, transfusion with infected blood products, and transmission from a pregnant mother to her baby.
What are the symptoms of Hepatitis E?
Symptoms of hepatitis E usually last for 1-6 weeks and include fever, jaundice (yellowing of whites of eyes and skin), reduced appetite, nausea and vomiting, abdominal pain, rash, itching, joint pain, dark urine and pale stools, and an enlarged, tender liver.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Hepatitis E?
While there is currently no cure for hepatitis E, most people get better without treatment within a few weeks; however, they should remain under the care of a doctor until fully recovered. Treatment for acute hepatitis E includes rest, drinking lots of fluids, and eating healthy foods.  Hospitalization is usually not required, with the exception of pregnant women and infected persons who have developed the severe complication known as fulminant hepatitis. Persons infected with hepatitis E must avoid taking medications that contain acetaminophen/paracetamol and drugs given for nausea and vomiting to prevent further liver damage. Do not drink alcohol until fully recovered. Immunosuppressed persons with chronic hepatitis E may be treated with the antiviral drug, ribavirin, or interferon. While a vaccine has been made for prevention of hepatitis E, it is currently only available in China.
Who are the top Hepatitis E Local Doctors?
Elite in Hepatitis E
Elite in Hepatitis E
Referral may be required

CHU Toulouse Rangueil

Toulouse, FR 

Nassim Kamar practices practicing medicine in Toulouse, France. Mr. Kamar is rated as an Elite expert by MediFind in the treatment of Hepatitis E. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Hepatitis E, Hepatitis, Cytomegalovirus Infection, Kidney Transplant, and Liver Transplant.

Elite in Hepatitis E
Elite in Hepatitis E
Referral may be required
Carl Neuberg Str. 1, 
Hannover, NI, DE 

Heiner Wedemeyer is a Hepatologist practicing medicine in Hannover, Germany. Mr. Wedemeyer is rated as an Elite expert by MediFind in the treatment of Hepatitis E. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Hepatitis D, Hepatitis, Hepatitis C, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hepatitis E
Elite in Hepatitis E
Referral may be required

CHU Purpan

Toulouse, FR 

Jacques Izopet practices practicing medicine in Toulouse, France. Mr. Izopet is rated as an Elite expert by MediFind in the treatment of Hepatitis E. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Hepatitis E, Hepatitis, Hereditary Neuralgic Amyotrophy, Kidney Transplant, and Liver Transplant.

View All Doctors
What are the latest Hepatitis E Clinical Trials?
A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants
A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants
Enrollment Status: Recruiting
Publish Date: July 27, 2026
Intervention Type: Drug, Other
Study Phase: Phase 1

Summary: This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects

Match to trials
Find the right clinical trials for you in under a minute
Get started
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Enrollment Status: Recruiting
Publish Date: January 22, 2026

Summary: RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies. RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health...

View All Clinical Trials